Market Place
Sourcing Support
Corcept’s Relacorilant Ph 3 Shows Cardiometabolic Improvements
16 Dec 2024 //
BUSINESSWIRE
Corcept`s Catalyst Trial Show Positive Result For Cushing’s Syndrome
12 Dec 2024 //
BUSINESSWIRE
Corcept spotlights Cushing syndrome in awareness campaign
12 Dec 2024 //
FIERCE PHARMA
Corcept Therapeutics` ALS drug fails in mid-stage trial
12 Dec 2024 //
REUTERS
Corcept Therapeutics` ALS drug fails in mid-stage trial
11 Dec 2024 //
REUTERS
Corcept Therapeutics Q3 Financial Results and Update Call
23 Oct 2024 //
BUSINESSWIRE
Corcept Therapeutics Announces Q2 Financial Results And Corporate Update
29 Jul 2024 //
GLOBENEWSWIRE
Corcept To Report Q2 Results And Host Corporate Update Call
22 Jul 2024 //
GLOBENEWSWIRE
Corcept Presents CATALYST Trial Results at ADA Scientific Sessions
24 Jun 2024 //
GLOBENEWSWIRE
Teva sues Corcept over mifepristone `monopoly` for rare disorder
14 Jun 2024 //
REUTERS
Corcept`s GRACE Relacorilant Hypercortisolism Phase 3 Data Presented
03 Jun 2024 //
GLOBENEWSWIRE
Corcept: GRACE Trial Met Primary Endpoint In Cushing`s Syndrome
28 May 2024 //
GLOBENEWSWIRE
Corcept Q1 Results, Corporate Update
01 May 2024 //
GLOBENEWSWIRE
Corcept Completes Enrollment in Phase 4 CATALYST Trial
29 Apr 2024 //
GLOBENEWSWIRE
Corcept to Report Q1 Results, Host Corporate Update Call
24 Apr 2024 //
GLOBENEWSWIRE
Corcept`s GRACE Cushing Study Open-Label Positive
22 Apr 2024 //
GLOBENEWSWIRE
Corcept Completes DAZALS ALS Phase 2 Enrollment
15 Apr 2024 //
GLOBENEWSWIRE
Corcept Completes Enrollment in Pivotal Ph 3 Trial of Relacorilant
08 Apr 2024 //
GLOBENEWSWIRE
Corcept Completes Enrollment in Ph 3 Trial of Relacorilant in ACS
01 Apr 2024 //
GLOBENEWSWIRE
Corcept Announces Fourth Quarter and Full-Year 2023 Audited Financial Results
15 Feb 2024 //
GLOBENEWSWIRE
Corcept to Announce Fourth Quarter and Full-Year 2023 Financial Results
08 Feb 2024 //
GLOBENEWSWIRE
Corcept Appoints Roberto Vieira as President, Oncology
29 Jan 2024 //
GLOBENEWSWIRE
Corcept Provides Financial Update and Announces Stock Repurchase Program
08 Jan 2024 //
GLOBENEWSWIRE
Corcept loses patent spat against Teva, shares tumble
02 Jan 2024 //
REUTERS
Corcept loses patent spat against Teva, shares tumble
29 Dec 2023 //
REUTERS
Corcept Therapeutics Announces Third Quarter Financial Results
01 Nov 2023 //
GLOBENEWSWIRE
Corcept Initiates MONARCH “ A Phase 2b Trial in NASH
26 Oct 2023 //
GLOBENEWSWIRE
Corcept Therapeutics to Announce Third Quarter Financial Results
25 Oct 2023 //
GLOBENEWSWIRE
Corcept Announces Second Quarter Financial Results and Provides Corporate Update
02 Aug 2023 //
GLOBENEWSWIRE
Corcept Therapeutics to Announce Second Quarter Financial Results
26 Jul 2023 //
GLOBENEWSWIRE
Corcepts Miricorilant Shows Great Promise in Treatment of NASH
17 Jul 2023 //
GLOBENEWSWIRE
Journal of Clinical Oncology Publishes Results of Corcept™s Ph2 of Relacorilant
27 Jun 2023 //
GLOBENEWSWIRE
Corcept Therapeutics Announces Final Results of Tender Offer
05 Apr 2023 //
GLOBENEWSWIRE
Corcept Therapeutics Announces Preliminary Results of Tender Offer
03 Apr 2023 //
GLOBENEWSWIRE
Corcept Therapeutics Initiates CATALYST Clinical Trial
28 Mar 2023 //
GLOBENEWSWIRE
Corcept Announces Tender Offer to Purchase up to 7,500,000 Shares
06 Mar 2023 //
GLOBENEWSWIRE
Corcept Announces Q4 and Full-Year 2022 Audited Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
Corcept to Announce Fourth Quarter and Full-Year 2022 Financial Results
14 Feb 2023 //
GLOBENEWSWIRE
Corcept Announces Settlement of Purported Securities Class Action Litigation
13 Feb 2023 //
GLOBENEWSWIRE
Corcept Therapeutics Provides Miricorilant Clinical Development Update
08 Dec 2022 //
GLOBENEWSWIRE
Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
08 Dec 2022 //
GLOBENEWSWIRE
Corcept Announces Third Quarter Financial Results and Provides Corporate
03 Nov 2022 //
PRESS RELEASE
Corcept Therapeutics to Announce Third Quarter Financial Results
27 Oct 2022 //
GLOBENEWSWIRE
Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in (ALS)
11 Oct 2022 //
GLOBENEWSWIRE
Corcept Therapeutics Announces Second Quarter Financial Results
03 Aug 2022 //
GLOBENEWSWIRE
Corcept Therapeutics to Announce Second Quarter Financial Results
27 Jul 2022 //
GLOBENEWSWIRE
Corcept Tx Initiates Rosella A PIII Trial in Ovarian Cancer
29 Jun 2022 //
GLOBENEWSWIRE
Corcept Therapeutics to Start PIII Trial of Relacorilant Plus Nab-Paclitaxel
06 Jun 2022 //
GLOBENEWSWIRE
Corcept Therapeutics Announces First Quarter Financial Results
05 May 2022 //
GLOBENEWSWIRE
Corcept Therapeutics to Announce First Quarter Financial Results
28 Apr 2022 //
GLOBENEWSWIRE
Corcept Therapeutics Announces Appointment of Three Senior Leaders
07 Apr 2022 //
GLOBENEWSWIRE
Corcept Closes Enrollment in Phase 2 Study on Antipsychotic-Induced Weight Gain
04 Apr 2022 //
GLOBENEWSWIRE
Corcept Tx to Host Ovarian Cancer Program Update on Thursday, March 31
01 Mar 2022 //
GLOBENEWSWIRE
Corcept Announces Q4 and Full-Year 2021 Audited Financial Results
15 Feb 2022 //
GLOBENEWSWIRE
Corcept Therapeutics Announces Final Results of Previously Tender Offer
20 Dec 2021 //
GLOBENEWSWIRE
Corcept Announces Preliminary Results of Previously Tender Offer
16 Dec 2021 //
GLOBENEWSWIRE
Corcept Therapeutics to Present at Upcoming Investor Conferences
10 Nov 2021 //
GLOBENEWSWIRE
Corcept Therapeutics Announces Commencement of Tender Offer to Purchase 10 M
08 Nov 2021 //
GLOBENEWSWIRE
Positive Results Presented at ESMO 2021 From Phase 2 Trial of Relacorilant
17 Sep 2021 //
GLOBENEWSWIRE
Corcept to present +ve Results From PII Trial of Relacorilant in Ovarian Cancer
09 Sep 2021 //
GLOBENEWSWIRE
